[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495471":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":21,"responsibleParty":35,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":51,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":23,"whyStopped":7,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Joyce Baard, MD, MSc","AmsterdamUMC","PRINCIPAL_INVESTIGATOR",[14,18],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","+31 020 444 0261","j.baard@amsterdamumc.nl",{"name":19,"role":15,"phone":16,"phoneExt":7,"email":20},"Orlane Figaroa, MD","o.j.figaroa@amsterdamumc.nl",[22],{"facility":11,"status":23,"city":24,"state":7,"zip":7,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"RECRUITING","Amsterdam","Netherlands","NL",{"type":28,"coordinates":29},"Point",[30,31],4.88969,52.37403,{"lat":31,"lon":30},[34],{"name":19,"role":15,"phone":7,"phoneExt":7,"email":20},{"type":12,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Joyce Baard","drs J. Baard Urologist (PI)","100495471","effect-of-a-si-mmc-on-the-ivr-rate-after-ureteroscopy-for-utuc-100495471",false,"NCT05731622","Effect of a SI-MMC on the IVR Rate After Ureteroscopy for UTUC","Effect of a Single Instillation of Mitomycin C on the Intravesical Recurrence Rate After Ureteroscopy for Upper Tract Urothelial Carcinoma: A Prospective, Multicenter Study","SINCERE","Inclusion Criteria:\n\n* All patients suspect for having non-metastatic disease and planned for ureteroscopy (diagnostic or treatment) and adjuvant single instillation of Mitomycin C\n* Age ≥18 years\n* Written informed consent\n\nExclusion Criteria:\n\n* History of histological proven urothelial carcinoma of the bladder, including carcinoma in situ\n* History of histological proven UTUC in the contralateral kidney\n* Concurrent bladder tumour found pre-operatively or per-operatively\n* Patients where it is not feasible to obtain histology by biopsies intra-operatively\n* Known Mitomycin C\n* Renal transplantation","ALL","18 Years",{"count":49,"type":50},100,"ESTIMATED","2 Years","OBSERVATIONAL","The goal of this observational study is to evaluate the intravesical recurrence (IVR) rate after ureteroscopy (diagnostic or treatment) for upper tract urothelial carcinoma (UTUC) followed by an adjuvant single instillation of Mitomycin C (SI-MMC).\n\nThe main question it aims to answer are:\n\n* What is the total and time to IVR after 2 years after ureteroscopy (diagnostic or treatment) for UTUC\n* How is the IVR compared with a historical cohort (no SI-MMC)\n* What is the time to IVR after 2 years in patients who subsequently received treatment by endoscopy vs. radical nephroureterectomy (RNU)\n* What is the additional value of a SI-MMC on time to IVR after RNU + adjuvant MMC in patients who were evaluated by ureteroscopy prior to RNU",[55],"Upper Urinary Tract Carcinoma",[57,58,59],"Intravesical recurrence","Mitomycin C","Ureteroscopy","2024-01-30",{"date":62,"type":63},"2024-01-31","ACTUAL",{"date":65,"type":50},"2024-02",{"date":67,"type":50},"2026-09",{"name":5,"class":6},1]